EFTA02112883.pdf

To: Rich Kahn From: Sent Mon 2/24/2014 8:46:48 PM Subject: Fwd: Joe Thakuria Begin forwarded message: From: Jeffrey Epstein <ieevacation@qmarl com> Subject: Re: Joe Thakuria Date: Februa 24, 2014 3:44:46 PM EST To: lets start and do the full genome with rapid turn around. 11, 400 On Mon, Feb 24, 2014 at 4:41 PM, wrote: Begin forwarded message: From: Joseph Thakuria Subject: Re: Jeffrey Epstein Date: Februa 24 2014 3:38:36 PM EST To: Cc: Rich Kahn Hi and Rich, Lesley, can you forward the following info to Jeffrey? So when I sent the initial invoice I didn't have the actual whole genome costs through Illumina which are $9500 for a normal turn around time and $11,400 for "rapid turn around time". The rapid turn around time isn't necessary in Jeffrey's case. And, in my opinion, if the budget is only $5000, I think the most bang for his buck (and this is what I would do for myself with only $5000 to spend) is to get an exome done. I should be able to get this through Ambry and through the same research protocol we'll be suing for the YPO study participants for $1000. I would then use the remainder to purchase genome analyses tools (there won't be enough for any servers) to perform secondary analyses on the exome. The exome only represents around 1.5% of the genome - but this is the medically most important part of the genome (at least given our current knowledge) and represents all the coding regions in all our 20,000+ genes. EFTA_R1_00735853 EFTA02112883 If this sounds good to Jeffrey, i'll produce a final budget before the end of the week that specifics which of the tools we'll be able to get with the remaining $4000. (I need to finish pricing and tallying up features among the 6 I listed to determine which one(s) will get. This won't of course cover any cellular work or other items in the full invoice but I would still recommend moving at least some fibroblast cell lines aliquots from the PGP to our new study so we can work on those when funding from other sources is available. I would also just throw out there for Jeffrey's consideration that the same ambitious protocol for a stripped down clinical next generation DNA sequencing laboratory could be pursued with a similar budget on the commercial side - and I've already been in discussion with others about funding this effort. Having followed this space since 2005 I can say the timing is very good for this type of business right now. Again, it hasn't even been more than a year that this technology has transitioned into clinical care. So if this is something Jeffrey would be interested in pursuing as an investor with an equity stake, rather than as a philanthropic grant for academic research, that would be another route for going ahead with the MI project that he may be interested in discussing further. Rich, I'll leave it to you on how you'd like to handle the $5000 invoice. I could receive this as a lump sum and account for how it is spent. I would expect all of it to be used up before the end of the summer. We can also arrange it so that as the various vendors (sequencing and software) provide invoices, your office pays them directly. Either way is fine with me. I don't have a preference. Thanks and let me know if I can provide any clarifications. Again, I'll follow up with an invoice capped at $5K before the end of the week (assuming you agree with the above). Joe Thakuria On Fri, Feb 21, 2014 at 6:34 PM, wrote: Hello Joe. I have Jeffrey's accountant on this email as well, Rich Kahn . Jeffrey has told Rich he would like to do a $5000 genetic work up done for the time being. Could you coordinate with Rich regarding payment/next steps? Thank you, EFTA_R1_00735854 EFTA02112884 Sent from my 'Phone The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA_R1_00735855 EFTA02112885